When the maker of a brand-name drug pays a maker of generic drugs to not produce a lower-priced version of their product, the Federal Trade Commission can challenge the arrangement on antitrust grounds, the Supreme Court ruled Monday. The ruling may end the era of what regulators call "pay-for-delay" deals.
The justices voted 5-3 to allow a case to go forward in which the FTC is challenging one of many such deals. Several companies are involved in the case, including Solvay Pharmaceuticals, maker of AndroGel, and generic-drug maker Actavis.
Ever since Iran's 1979 Islamic Revolution, the U.S. has been in search of moderate Iranian leaders who could steer the country away from its hostile standoff with America.
To cite one famous example, President Ronald Reagan's administration secretly sold weapons to Iran in the mid-1980s in the belief it could work with the country's "moderate" elements even as Iran remained under the control of revolutionary leader Ayatollah Ruhollah Khomeini.